Glioblastoma stem-like cells secrete the pro-angiogenic VEGF-A factor in extracellular vesicles

Journal of Extracellular Vesicles

Volumn 6, Issue 1, 2017, Pages

  Treps, Lucas ^a   Perret, Raul ^b   Edmond, Sébastien ^c   Ricard, Damien ^a,c,d   Gavard, Julie ^a,b  

^a CNRS   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c PERCY MILITARY HOSPITAL   (France)

^d 2ème Centre Médical des Armées   (France)

Author keywords

angiogenesis; cancer stem like cells; circulating vesicles; exosomes; glioma; GSC; microparticles; microvesicles; VEGF

Indexed keywords

CD63 ANTIGEN; VASCULOTROPIN A;

AGED; ANGIOGENESIS; ARTICLE; CANCER PROGNOSIS; CELL MEMBRANE PERMEABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EXOSOME; GLIOBLASTOMA; GLIOMA STEM CELL; HBEC CELL LINE (BRAIN); HUMAN; HUMAN CELL; IN VITRO STUDY; MALE;

EID: 85040714285     PISSN: None     EISSN: 20013078     Source Type: Journal    
DOI: 10.1080/20013078.2017.1359479     Document Type: Article

References (74)

1. Cloughesy TF, Cavenee WK, Mischel PS., Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol. 2014;9:1–12.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996.
3. Yuan X, Curtin J, Xiong Y, et al. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene. 2004;23(58):9392–9400.
4. Lathia JD, Mack SC, Mulkearns-Hubert EE, et al. Cancer stem cells in glioblastoma. Genes Dev. 2015;29(12):1203–1217.
5. Kreso A, Dick JE., Evolution of the cancer stem cell model. Cell Stem Cell. 2014;14(3):275–291.
6. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11(1):69–82.
7. Galan-Moya EM, Le Guelte A, Fernandes EL, et al. Secreted factors from brain endothelial cells maintain glioblastoma stem-like cell expansion through the mTOR pathway. EMBO Rep. 2011;12(5):470–476.
8. Galan-Moya EM, Treps L, Oliver L, et al. Endothelial secreted factors suppress mitogen deprivation-induced autophagy and apoptosis in glioblastoma stem-like cells. PLoS One. 2014;9(3):e93505.
9. Fessler E, Borovski T, Medema JP. Endothelial cells induce cancer stem cell features in differentiated glioblastoma cells via bFGF. Mol Cancer. 2015;14:157.
10. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709–722.
11. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699–708.
12. Batchelor TT, Reardon DA, De Groot JF, et al. Antiangiogenic therapy for glioblastoma: current status and future prospects. Clin Cancer Res. 2014;20(22):5612–5619.
13. Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 2006;66(16):7843–7848.
14. Folkins C, Shaked Y, Man S, et al. Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res. 2009;69(18):7243–7251.
15. Treps L, Edmond S, Harford-Wright E, et al. Extracellular vesicle-transported Semaphorin3A promotes vascular permeability in glioblastoma. Oncogene. 2016;35(20):2615–2623.
16. Le Guelte A, Galan-Moya E-M, Dwyer J, et al. Semaphorin 3A elevates endothelial cell permeability through PP2A inactivation. J Cell Sci. 2012;125(Pt 17):4137–4146.
17. Yanez-Mo M, Siljander PR, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015;4:27066.
18. Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30:255–289.
19. Bronisz A, Godlewski J, Chiocca EA. Extracellular vesicles and MicroRNAs: their role in tumorigenicity and therapy for brain tumors. Cell Mol Neurobiol. 2016;36(3):361–376.
20. Chistiakov DA, Chekhonin VP. Extracellular vesicles shed by glioma cells: pathogenic role and clinical value. Tumour Biol. 2014;35(9):8425–8438.
21. Andre-Gregoire G, Gavard J. Spitting out the demons: extracellular vesicles in glioblastoma. Cell Adh Migr. 2016;13:1–9.
22. Skog J, Würdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10(12):1470–1476.
23. Kucharzewska P, Christianson HC, Welch JE, et al. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc Natl Acad Sci U S A. 2013;110(18):7312–7317.
24. Halin Bergström S, Hägglöf C, Thysell E, et al. Extracellular vesicles from metastatic rat prostate tumors prime the normal prostate tissue to facilitate tumor growth. Sci Rep. 2016;6:31805.
25. Chow A, Zhou W, Liu L, et al. Macrophage immunomodulation by breast cancer-derived exosomes requires Toll-like receptor 2-mediated activation of NF-κB. Sci Rep. 2015;4:5750.
26. Yang N, Li S, Li G, et al. The role of extracellular vesicles in mediating progression, metastasis and potential treatment of hepatocellular carcinoma. Oncotarget. 2017;8:3683–3695.
27. Tkach M, Théry C. Communication by extracellular vesicles: where we are and where we need to go. Cell. 2016;164(6):1226–1232.
28. Witwer KW, Buzas EI, Bemis LT, et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles. 2013;2: DOI:10.3402/jev.v2i0.20360.
29. Yoshioka Y, Konishi Y, Kosaka N, et al. Comparative marker analysis of extracellular vesicles in different human cancer types. J Extracell Vesicles. 2013;2: DOI:10.3402/jev.v2i0.20424.
30. Weksler BB, Subileau EA, Perrière N, et al. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 2005;19(13):1872–1874.
31. Goodwin AM. In vitro assays of angiogenesis for assessment of angiogenic and anti-angiogenic agents. Microvasc Res. 2007;74(2–3):172–183.
32. Le Guelte A, Dwyer J, Gavard J. Jumping the barrier: VE-cadherin, VEGF and other angiogenic modifiers in cancer. Biol Cell. 2011;103(12):593–605.
33. Muller L, Muller-Haegele S, Mitsuhashi M, et al. Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival. Oncoimmunology. 2015;4(6):e1008347.
34. Vallabhaneni KC, Penfornis P, Dhule S, et al. Extracellular vesicles from bone marrow mesenchymal stem/stromal cells transport tumor regulatory microRNA, proteins, and metabolites. Oncotarget. 2015;6(7):4953–4967.
35. Lo Cicero A, Majkowska I, Nagase H, et al. Microvesicles shed by oligodendroglioma cells and rheumatoid synovial fibroblasts contain aggrecanase activity. Matrix Biol. 2012;31(4):229–233.
36. Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146(5):1029–1039.
37. Nagy JA, Benjamin L, Zeng H, et al. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis. 2008;11(2):109–119.
38. Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999;59(1):99–106.
39. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24(1):25–35.
40. Zhang S-D, Leung KL, McCrudden CM, et al. The prognostic significance of combining VEGFA, FLT1 and KDR mRNA expressions in brain tumors. Journal of Cancer. 2015;6(9):812–818.
41. Hamerlik P, Lathia JD, Rasmussen R, et al. Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med. 2012;209(3):507–520.
42. Bhattacharya R, Ye X-C, Wang R, et al. Intracrine VEGF signaling mediates the activity of prosurvival pathways in human colorectal cancer cells. Cancer Res. 2016;76(10):3014–3024.
43. Lichtenberger BM, Tan PK, Niederleithner H, et al. Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell. 2010;140(2):268–279.
44. Schoeffner DJ, Matheny SL, Akahane T, et al. VEGF contributes to mammary tumor growth in transgenic mice through paracrine and autocrine mechanisms. Lab Invest. 2005;85(5):608–623.
45. Bachelder RE, Crago A, Chung J, et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res. 2001;61(15):5736–5740.
46. Cao Y, Guangqi E, Wang E, et al. VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression. Cancer Res. 2012;72(16):3912–3918.
47. Zhou R, Curry JM, Roy LD, et al. A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: role in induction of VEGF signaling and angiogenesis. Oncogene. 2016;35(43):5608–5618.
48. Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer. 2013;13(12):871–882.
49. Garcia-Romero N, Carrion-Navarro J, Esteban-Rubio S, et al. DNA sequences within glioma-derived extracellular vesicles can cross the intact blood-brain barrier and be detected in peripheral blood of patients. Oncotarget. 2016.
50. Shao H, Chung J, Balaj L, et al. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med. 2012;18(12):1835–1840.
51. Setti M, Osti D, Richichi C, et al. Extracellular vesicle-mediated transfer of CLIC1 protein is a novel mechanism for the regulation of glioblastoma growth. Oncotarget. 2015;6(31):31413–31427.
52. Giusti I, Delle Monache S, Di Francesco M, et al. From glioblastoma to endothelial cells through extracellular vesicles: messages for angiogenesis. Tumour Biol. 2016;37(9):12743–12753.
53. Taraboletti G, D’Ascenzo S, Giusti I, et al. Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH. Neoplasia. 2006;8(2):96–103.
54. Parolini I, Federici C, Raggi C, et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem. 2009;284(49):34211–34222.
55. Cossetti C, Iraci N, Mercer TR, et al. Extracellular vesicles from neural stem cells transfer IFN-gamma via Ifngr1 to activate Stat1 signaling in target cells. Mol Cell. 2014;56(2):193–204.
56. Feng Q, Zhang C, Lum D, et al. A class of extracellular vesicles from breast cancer cells activates VEGF receptors and tumour angiogenesis. Nat Commun. 2017;8:14450.
57. Xu C, Wu X, Zhu J. VEGF promotes proliferation of human glioblastoma multiforme stem-like cells through VEGF receptor 2. Scientific World J. 2013;2013:417413.
58. Li Q, Qiao G, Ma J, et al. Downregulation of VEGF expression attenuates malignant biological behavior of C6 glioma stem cells. Int J Oncol. 2014;44(5):1581–1588.
59. Grun D, Adhikary G, Eckert RL. VEGF-A acts via neuropilin-1 to enhance epidermal cancer stem cell survival and formation of aggressive and highly vascularized tumors. Oncogene. 2016;35(33):4379–4387.
60. Liu S, Sun J, Lan Q. Glioblastoma microvesicles promote endothelial cell proliferation through Akt/beta-catenin pathway. Int J Clin Exp Pathol. 2014;7(8):4857–4866.
61. Rinkenbaugh AL, Cogswell PC, Calamini B, et al. IKK/NF-kappaB signaling contributes to glioblastoma stem cell maintenance. Oncotarget. 2016.
62. Anido J, Saez-Borderias A, Gonzalez-Junca A, et al. TGF-beta receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell. 2010;18(6):655–668.
63. Zhang M, Kleber S, Rohrich M, et al. Blockade of TGF-beta signaling by the TGFbetaR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res. 2011;71(23):7155–7167.
64. Podergajs N, Brekka N, Radlwimmer B, et al. Expansive growth of two glioblastoma stem-like cell lines is mediated by bFGF and not by EGF. Radiol Oncol. 2013;47(4):330–337.
65. Rafat N, Beck G, Schulte J, et al. Circulating endothelial progenitor cells in malignant gliomas. J Neurosurg. 2010;112(1):43–49.
66. Chen X, Fang J, Wang S, et al. A new mosaic pattern in glioma vascularization: exogenous endothelial progenitor cells integrating into the vessels containing tumor-derived endothelial cells. Oncotarget. 2014;5(7):1955–1968.
67. Tseng J-C, Chang L-C, Jiang B-Y, et al. Elevated circulating levels of tissue factor-positive microvesicles are associated with distant metastasis in lung cancer. J Cancer Res Clin Oncol. 2014;140(1):61–67.
68. Wendler F, Favicchio R, Simon T, et al. Extracellular vesicles swarm the cancer microenvironment: from tumor-stroma communication to drug intervention. Oncogene. 2017;36:877–884.
69. Westphal M, Lamszus K. Circulating biomarkers for gliomas. Nat Rev Neurol. 2015;11(10):556–566.
70. Azzi S, Treps L, Leclair HM, et al. Desert hedgehog/patch2 axis contributes to vascular permeability and angiogenesis in glioblastoma. Front Pharmacol. 2015;6:281.
71. Dwyer J, Azzi S, Leclair HM, et al. The guanine exchange factor SWAP70 mediates vGPCR-induced endothelial plasticity. Cell Commun Signal. 2015;13(1):11.
72. Treps L, Gavard J. Assaying the action of secreted semaphorins on vascular permeability. Methods Mol Biol. 2017;1493:417–427.
73. Leclair HM, Andre-Gregoire G, Treps L, et al. E3 ubiquitin ligase MARCH3 controls the endothelial barrier. FEBS Lett. 2016;590(20):3660–3668.
74. Bowman RL, Wang Q, Carro A, et al. Squatrito M. GlioVis data portal for visualization and analysis of brain tumor expression datasets. Neuro Oncol. 2017;19(1):139–141.